Sort
23,748 grants matching “melanoma”
TLR5 signaling as a conserved mechanism of impaired anti-tumor immunity
$402,753Melanie R Rutkowski · University Of Virginia · R01 · FY2023 · CA
MECHANISMS OF UV-INDUCED MELANOMA INITIATION. NEW AWARD.
$402,732University Of Utah · · FY2020 · Department of the Army
Using gene expression profiles to elucidate mechanisms of melanoma progression
$402,693Ashani Weeraratna · National Institute On Aging · Z01 · FY2008 · AG
Lipid programs in melanocyte transformation
$402,618Michael H. Overholtzer · Sloan-Kettering Inst Can Research · R01 · FY2023 · CA
Studies on the effects of a novel intermittent therapy on intratumoral clonal architecture and resistance
$402,618Piro Lito · Sloan-Kettering Inst Can Research · R01 · FY2023 · CA
Lipid programs in melanocyte transformation
$402,618Richard Mark White · Sloan-Kettering Inst Can Research · R01 · FY2022 · CA
Establishing MAGE-A4/RAD18 as a novel cancer-specific chemotherapeutic target
$402,605Cyrus Vaziri · Univ Of North Carolina Chapel Hill · R01 · FY2021 · CA
Targeting Vulnerabilities Exposed by Cancer Treatment-Induced Lineage Plasticity
$402,600Peter S Nelson · Fred Hutchinson Cancer Center · R01 · FY2025 · CA
Targeting Vulnerabilities Exposed by Cancer Treatment-Induced Lineage Plasticity
$402,600Peter S Nelson · Fred Hutchinson Cancer Center · R01 · FY2022 · CA
ATF2 in melanoma development and progression
$402,590Ze'ev A Ronai · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2011 · CA
(PQ5) Mitochondria are endocellular symbionts that serve as targets for immune recognition
$402,548Andrea Facciabene · University Of Pennsylvania · R01 · FY2017 · CA
64-Bit High Performance Computing
$402,523Edward B Suh · Translational Genomics Research Inst · S10 · FY2007 · RR
Role of p53 and ptc tumor suppressive pathways in BCCs development and prevention
$402,500Mohammad Athar · Columbia University Health Sciences · R01 · FY2006 · ES
Identification and cloning of neoantigen-specific T cells for GBM immunotherapy
$402,460Robert M Prins · University Of California Los Angeles · R01 · FY2023 · CA
Identification and cloning of neoantigen-specific T cells for GBM immunotherapy
$402,457Robert M Prins · University Of California Los Angeles · R01 · FY2022 · CA
In situ radioimmunotherapy to maximize the engagement of conventional type 1 dendritic cells against non-T cell-inflamed tumors
$402,417Fumito Ito · University Of Southern California · R01 · FY2022 · CA
Antitumor potential of AvFc lectibody in non-small cell lung cancer
$402,402Nobuyuki Matoba · University Of Louisville · R21 · FY2023 · CA
Dissecting the structure-function relationship of the Wnt destruction complex condensate
$402,400Maxwell Zane Wilson · University Of California Santa Barbara · R21 · FY2025 · CA
Novel Immunologic Effects of Semaphorin 7a in IPF
$402,385Erica L Herzog · Yale University · R01 · FY2014 · HL
FOCAL ADHESION KINASE--TUMOR BIOLOGY AND THERAPEUTICS
$402,379University Of Florida · R01 · FY2003 · CA
SOUTHWEST ONCOLOGY GROUP--SUMMARY
$402,352Loyola University Chicago · U10 · FY2003 · CA
Substrate Specificity Determinants in Nutrient Solute Carrier Transporters
$402,346Avner Schlessinger · Icahn School Of Medicine At Mount Sinai · R01 · FY2024 · CA
A prognostic mRNA immune signature for resected stage II-III melanoma
$402,257Yvonne Margaret Saenger · Albert Einstein College Of Medicine · UH3 · FY2022 · CA
Evaluation of Immune-based Combinations in Metastatic Prostate Cancer
$402,223Ravi Madan · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
Controlled Release of Macromolecules
$402,150Robert S Langer · Massachusetts Institute Of Technology · R37 · FY2010 · EB